16.
NewLimit raises $435M to treat cellular aging as disease (x.com)
A $3.1B valuation for NewLimit signals that epigenetic reprogramming and aging biology have moved from speculative longevity research into large-scale company building
@maxime_bucaille on Backlist
1 appearance on the backlist front page in the last 30 days.